Reported results
- Research and development expenses were $47.1 million for the three months ended September 30, 2026, compared to $39.8 million for the same period in 2025.
- General and administrative expenses were $7.6 million for the three months ended September 30, 2026, compared to $6.8 million for the same period in 2025.
- Net loss was $53.1 million for the three months ended September 30, 2026, compared to $44.9 million for the same period in 2025.
- Net loss per common stock share, basic and diluted, was $(0.28) for the three months ended September 30, 2026, compared to $(0.44) for the same period in 2025.
- Cash, cash equivalents and short-term investments were $299.4 million as of September 30, 2026.
Guidance
- The Company expects that its cash position as of September 30, 2026, will enable it to fund its operating plan into the first quarter of 2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
